IDEAYA Biosciences – Fact Sheet

Founded 2015 on the thesis that Synthetic Lethality would emerge as a central focus of precision medicine oncology, with significant Pharma interest and the potential to develop *first-in-class* therapeutics for biomarker-defined cancer patient populations.

Broad Pipeline of clinical and preclinical precision medicine oncology programs with defined patient biomarkers, including

- *IDE397* targeting MAT2A for patients having tumors with MTAP deletion, a population estimated to represent ~ 15% of all solid tumors,
- *Pol Theta* for patients with tumors having mutations in BRCA or other homologous recombination deficiency,
- *PARG* for patients having tumors with BRCA2 mutations or other genetic and/or molecular signatures,
- *Werner Helicase* for patients having tumors with high microsatellite instability,
- MTAP-SL and DNA Damage Targets (DDT1, DDT2), undisclosed synthetic lethality targets for molecularly-defined patient populations, and
- *Darovasertib (IDE196)* targeting PKC for patients having metastatic uveal melanoma (MUM) or GNAQ /GNA11-mutation skin melanoma.

Proven Management Team with deep business and scientific experience has built leading oncology biotech companies, led by CEO Yujiro S. Hata, M.B.A., an entrepreneur with over 20 years of experience building companies that have delivered innovative therapies to patients.

Scientific Advisory Board includes world-class scientists who are key opinion leaders in precision medicine oncology and synthetic lethality, including Alan D'Andrea, M.D. (Harvard, Dana Farber), Bill Sellers, M.D. (Broad Institute, Novartis), and Frank McCormick, Ph.D. (UCSF).

Pharma Strategic Partnerships and Collaborations with GlaxoSmithKline[1] and Pfizer[2]. The GSK strategic partnership validates IDEAYA's Synthetic Lethality platform and enhances the companies' collective leadership in Synthetic Lethality. IDEAYA and GSK are collaborating on three programs – *MAT2A, Pol Theta* and *Werner Helicase*. IDEAYA retains commercial rights of 50% US profit-share and ex-US royalties for *MAT2A* and *Werner Helicase*, and worldwide royalties for *Pol Theta*, with potential to earn up to approximately $3 billion in aggregate cash milestones across the three programs.

Strong Balance Sheet of ~$400 million[3] with capital efficient model is anticipated to fund planned operations into 2025, supporting clinical data milestones across multiple programs, including for *IDE397* – targeting MAT2A in MTAP-deletion tumors and for darovasertib – targeting PKC in Metastatic Uveal Melanoma (MUM) and other GNAQ/11 mutation tumors, such as skin melanoma

Analyst Coverage by JP Morgan, Guggenheim, Jefferies, Oppenheimer, Northland, Roth, RW Baird, HC Wainwright and Wedbush.

(1) GSK Collaboration, Option and License Agreement; (2) Pfizer Clinical Trial Collaboration and Supply Agreement: (3) Includes cash, cash equivalents and marketable securities of $312.4M as of June 30, 2021, and subsequent $86.5M estimated net proceeds, after deducting underwriting discounts and commissions but before deducting other offering expenses, from issuance of shares under an underwritten public offering pursuant to IDEAYA Form 10Q and Q2 2021 Financials (August 10, 2021)